

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph no. [0001] with the following amended paragraph:

[0001] This application is a continuation of pending application Ser. No. ~~40/420,054~~
10/420,057 filed Apr. 18, 2003 which is a continuation of application Ser. No. 09/667,199 filed
Sep. 21, 2000, now U.S. Pat. No. 6,565,509 B1, which is a continuation of application Ser. No.
09/070,677 filed Apr. 30, 1998 now U.S. Pat. No. 6,175,752 B1, the disclosure of each of which
are incorporated herein by reference for all purposes, and each of which are assigned to assignee,
TheraSense, Inc., of Alameda, California.

Please delete the present Abstract of the Disclosure.

Please add the following new Abstract of the Disclosure:

An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. ~~The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.~~